Researchers at the Duke University Medical Center have discovered that HIV patients who take fewer pills tend to do better than patients on a more complex medical regimen. Based on an analysis of more than 3,000 patients involved in triple-drug combination trials to treat HIV infection, researchers speculate that patients who take fewer pills, as few as four a day, are more likely to adhere to their medication regimen - and therefore receive the greatest benefits of the therapy – than those on complex regimens who must take up to 16 pills at different times during the day.
Researchers at the Duke University Medical Center have discovered that HIV patients who take fewer pills tend to do better than patients on a more complex medical regimen. Based on an analysis of more than 3,000 patients involved in triple-drug combination trials to treat HIV infection, researchers speculate that patients who take fewer pills, as few as four a day, are more likely to adhere to their medication regimen - and therefore receive the greatest benefits of the therapy â than those on complex regimens who must take up to 16 pills at different times during the day.
"This study is an affirmation of our clinical experience that simpler regimens may lead to better treatment outcomes," said Dr. John Bartlett, director of clinical research at the Duke University Center for AIDS Research. "The results of the current study would seem to emphasize the importance of developing drug regimens that are simple, potent and easy for patients to take.
"We assume that the reason for better outcomes is improved adherence," Bartlett continued. "Other studies have shown that fewer pills can lead to better adherence, but this is the first to demonstrate a link to better outcomes."
In clinical trials for antiretroviral agents, the key indicator of success is the number of copies of HIV genetic material detectable in the blood. The number indicates how the virus is replicating, and for the study, less than 50 copies per milliliter of blood indicates that a medication has been successful.
"We found that about 75% of patients on the simplest regimens had less than 50 copies of HIV RNA in their blood," Bartlett said. "In comparison, only about 20% of patients with the most complex regimens had less than 50 copies. We know that levels less than 50 are an important indicator of a durable response to the medications."
Concluded Bartlett: "We controlled for the kinds of drugs that were being used and their combinations. Even after this analysis, the pill count was still a statistically significant indicator of patient outcome." PR
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.